

Important reminder

Transition period ending for Drug Product(s) removed from the April 1, 2016 Alberta Drug Benefit List (ADBL) as the Manufacturer did not submit a Price to the annual Alberta Price Confirmation Process:

As per the Alberta Price Policy, Manufacturers with drug products currently listed in Alberta were invited to re-quote the price of their drug product(s) for continued listing. As advised in Benefact 597 issued on March 30, 2016, the following Drug Products were removed from the ADBL for Alberta government-sponsored drug programs effective April 1, 2016 as these Manufacturers have chosen not to re-confirm their price.

All Drug Products removed from the ADBL effective April 1, 2016 have been identified as having therapeutic alternatives. A 30 day transition period was applied to allow physicians, pharmacists and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate and, as of April 30, 2016, claims will no longer be paid for these products. Patients impacted by the removal of these Drug Products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

DIN/PIN	Product description
02397145	ACT Diclo-Miso 50 mg/200 mcg Enteric-Coated Tablet
02397153	ACT Diclo-Miso 75 mg/200 mcg Enteric-Coated Tablet
00180408	Aldactazide-25 Tablet
00594377	Aldactazide-50 Tablet
00028606	Aldactone 25 mg Tablet
00285455	Aldactone 100 mg Tablet
02381931	Auro-Ciprofloxacin 750 mg Tablet
02187086	Brevicon 0.5/35 (21 Day) Tablet
02187094	Brevicon 0.5/35 (28 Day) Tablet
02189054	Brevicon 1/35 (21 Day) Tablet
02189062	Brevicon 1/35 (28 Day) Tablet
01958100	Cardura 1 mg Tablet
01958097	Cardura 2 mg Tablet
01958119	Cardura 4 mg Tablet
02237137	Cefazolin 500 mg/Vial USP Injection
00642975	Colestid Oral Powder Packet
02132699	Colestid Orange 7.5 g Oral Powder Packet
02064405	Cyklokapron 500 mg Tablet
00030570	Dalacin C 150 mg Capsule
02182866	Dalacin C 300 mg Capsule

... continued from previous page

DIN/PIN	Product description
00030848	Depo-Provera 50 mg/ml Injection
00607142	Eryc 250 mg Capsule (Enteric-Coated Pellet)
02042320	Min-Ovral (21 Day) Tablet
02042339	Min-Ovral (28 Day) Tablet
00708917	Provera 2.5 mg Tablet
00030937	Provera 5 mg Tablet
00729973	Provera 10 mg Tablet
02064480	Salazopyrin 500 mg Tablet
02064472	Salazopyrin EN-Tabs 500 mg Enteric-Coated Tablet
02197502	Select 1/35 (21 Day) Tablet
02199297	Select 1/35 (28 Day) Tablet
00511234	Tromboject 10 mg/ml Injection
00548359	Xanax 0.25 mg Tablet
00548367	Xanax 0.5 mg Tablet
02413701	Zoledronic Acid Concentrate 4 mg/5 ml Injection

Additionally, the transition period is also ending for Drug Product(s) removed from the April 1, 2016 ADBL as they were discontinued by the Manufacturer:

Notification of discontinuation has been received from the manufacturers and effective April 1, 2016, the following Drug Products were no longer a benefit. A 30 day transition period was applied to allow physicians, pharmacists and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate and, as of April 30, 2016, claims will no longer be paid for these products. Patients impacted by the discontinuation of these Drug Products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

DIN/PIN	Product description
02244817	ACT Clomipramine 25 mg Tablet
02244818	ACT Clomipramine 50 mg Tablet
02040778	Apo-Clomipramine 25 mg Tablet
02040751	Apo-Clomipramine 50 mg Tablet
02059762	Aredia 30 mg/Vial Injection
02059789	Aredia 90 mg/Vial Injection
02065614	Diazemuls 5 mg/ml Emulsion Injection
02352400	Diclofenac Sodium SR 75 mg Tablet
00610100	Fluor-A-Day 5.56 mg/ml Oral Drops
02245330	Mylan-Etidronate 200 mg Tablet
00999521	Nutramigen A+ Hypoallergenic Infant Formula Liquid
00999347	Nutrihep Oral Liquid
02268027	Ran-Carvedilol 3.125 mg Tablet
02268035	Ran-Carvedilol 6.25 mg Tablet
02268043	Ran-Carvedilol 12.5 mg Tablet
02268051	Ran-Carvedilol 25 mg Tablet
02405695	Ran-Fluoxetine 10 mg Capsule
02405709	Ran-Fluoxetine 20 mg Capsule
02233982	Sandoz Clonazepam 1 mg Tablet
02400243	Sandoz Fluvastatin 40 mg Capsule

continued on next page ...

... continued from previous page

02268205	Twinject 1:1000 (0.15 mg) Injection Auto Injector
02247310	Twinject 1:1000 (0.3 mg) Injection Auto Injector
00024368	Vibramycin 100 mg Capsule
02370816	Vitreleis 200 mg Capsule
02371448	Vitreleis Triple (Kit) 200 mg/200 mg/80 mcg/0.5 ml Injection Syringe/Capsule
02371456	Vitreleis Triple (Kit) 200 mg/200 mg/100 mcg/0.5 ml Injection Syringe/Capsule
02371464	Vitreleis Triple (Kit) 200 mg/200 mg/120 mcg/0.5 ml Injection Syringe/Capsule
02371472	Vitreleis Triple (Kit) 200 mg/200 mg/150 mcg/0.5 ml Injection Syringe/Capsule

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.605 2016/05

